



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

VR23

Cat. No.:	HY-18741
CAS No.:	1624602-30-7
Molecular Formula:	C ₁₉ H ₁₆ ClN ₅ O ₆ S
Molecular Weight:	477.88
Target:	Proteasome; Apoptosis
Pathway:	Metabolic Enzyme/Protease; Apoptosis
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 33.33 mg/mL (69.75 mM; Need ultrasonic)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.0926 mL	10.4629 mL	20.9258 mL
	5 mM		0.4185 mL	2.0926 mL	4.1852 mL
	10 mM		0.2093 mL	1.0463 mL	2.0926 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	VR23 is a small molecule that potently inhibits the activities of trypsin-like proteasomes (IC ₅₀ =1 nM), chymotrypsin-like proteasomes (IC ₅₀ =50-100 nM), and caspase-like proteasomes (IC ₅₀ =3 μM).
IC ₅₀ & Target	IC ₅₀ : 1 nM (trypsin-like proteasome), 50-100 nM (chymotrypsin-like proteasome), 3 μM (caspase-like proteasome)
In Vitro	VR23 is a novel proteasome inhibitor targeting β2 of the 20S proteasome subunit. VR23 produces a synergistic effect in killing multiple myeloma cells, including those that were resistant to PS-341. VR23 as a structurally novel proteasome inhibitor with desirable properties as an anticancer agent. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	VR23 shows effective antitumor and antiangiogenic activities in mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Pundir S, et al. VR23: A Quinoline-Sulfonyl Hybrid Proteasome Inhibitor That Selectively Kills Cancer via Cyclin E-Mediated Centrosome Amplification. Cancer Res. 2015 Oct 1;75(19):4164-4175.

[2]. Lee Hoyun, et al. Preparation of quinoline sulfonyl derivatives for the treatment of cancer. From PCT Int. Appl. (2014), WO 2014134705 A1 20140912.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA